Study #2023-0082
A phase 1 study of oral PCLX-001 in relapsed/refractory (R/R) acute myeloid leukemia (AML)
MD Anderson Study Status
Enrolling
Treatment Agent
zelenirstat
Description
This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed Adult AML
Study phase:
Phase I
Physician name:
Naveen Pemmaraju
Department:
Leukemia
For general questions about clinical trials:
1-844-897-9044
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.